Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.51 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.44 |
| ▸ | DGKA | P23743 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14957317 | 1.00 | PRKCA (0.51) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL30168486 | 0.93 | PRKCA (0.61) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL11221318 | 0.93 | PRKCA (0.61) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL14718529 | 0.93 | PRKCA (0.61) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL2701578 | 0.93 | PRKCA (0.61) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL29577299 | 0.93 | PRKCA (0.61) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL1285953 | 0.93 | PRKCA (0.61) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL8389087 | 0.93 | PRKCA (0.61) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL6565430 | 0.91 | PRKCA (0.59) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL30553865 | 0.89 | ENPP2 (0.60) | ALDH1A1ENPP2LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6864252-B2 | Hydrazinyl and nitrogen oxide pyrazoles | PFIZER, INC. (US) | 2005-03-08 | — | — | US | claimed |
| US-6861060-B1 | Personal care formulations | KARMALI, RASHIDA A. | 2005-03-01 | — | — | US | claimed |
| US-20030134850-A1 | Hydrazinyl and nitrogen oxide pyrazoles | PFIZER INC. | 2003-07-17 | — | — | US | claimed |
| EP-1308158-A1 | Sulfonylaryl- and sulfonylheteroaryl-pyrazoles with a hydrazinyl or nitrogen oxide substituent at the 5-position for use as cyclooxygenase inhibitors | Pfizer Productors Inc. (US) | 2003-05-07 | — | — | EP | claimed |
| WO-2020220141-A1 | CANNABINOID STOCK TRANSDERMAL FORMULATIONS | BETTERLIFE PHARMA INC. (CA) | 2020-11-05 | — | — | WO | disclosed |
| US-20200345657-A1 | CANNABINOID STOCK FOR FORMULATION PRODUCTS | BETTERLIFE PHARMA INC. (CA) | 2020-11-05 | — | — | US | disclosed |
| US-6864252-B2 | Hydrazinyl and nitrogen oxide pyrazoles | PFIZER, INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-20030134850-A1 | Hydrazinyl and nitrogen oxide pyrazoles | PFIZER INC. | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134850-A1 | Hydrazinyl and nitrogen oxide pyrazoles | NOX5, ARG1, NOS1 | PRKCA 4241/4885PRKCE 3983/4885PRKCQ 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.